MED|420 with CNW – Clinical Trials of Cannabis as a Treatment for Pancreatic Cancer Expected

420 with CNW – Clinical Trials of Cannabis as a Treatment for Pancreatic Cancer Expected

The United States Food and Drug Administration has granted a flavonoid of cannabis (Caflanone) the status of the Orphan Drug. It is estimated that within the next few months, the approved Orphan Drug will be used in clinical trials for treating pancreatic cancer. The clinical trials will involve human subjects. Flavocure is a drug innovation and development company. The company developed the cannabis flavonoid Caflanone (FBL-03G). The U.S. Food and Drug Administration granted Caflanone the Orphan drug status after it was successful in reducing tumor progression in animals with pancreatic cancer through therapy. The Executive Chairman of Flavocure, Dr. Henry Lowe, said that the company is happy for the designation of Orphan Drug status by the FDA for Caflanone. He further noted that the appointment is a momentous breakthrough for the Flavocure innovation and drug development program. Dr. Lowe also said that they expect to start a clinical trial involving human subjects with the New Investigational Drug in the next few months. The clinical trials will be addressing pancreatic cancer. He added that a new standard of care is required for effective and innovative treatment of pancreatic cancer, and as a recognized leader in the field of drug discovery and…

Excerpt only …
READ MORE BELOW
Source : New feed
Link to original : 420 with CNW – Clinical Trials of Cannabis as a Treatment for Pancreatic Cancer Expected
reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.